DE69920697D1 - Adenosinderivate - Google Patents

Adenosinderivate

Info

Publication number
DE69920697D1
DE69920697D1 DE69920697T DE69920697T DE69920697D1 DE 69920697 D1 DE69920697 D1 DE 69920697D1 DE 69920697 T DE69920697 T DE 69920697T DE 69920697 T DE69920697 T DE 69920697T DE 69920697 D1 DE69920697 D1 DE 69920697D1
Authority
DE
Germany
Prior art keywords
adenosine derivatives
adenosine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920697T
Other languages
English (en)
Other versions
DE69920697T2 (de
Inventor
David Edmund Bays
Richard Peter Charles Cousins
Hazel Joan Dyke
Colin David Eldred
Brian David Judkins
Martin Pass
Andrew Michael K Pennell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE69920697D1 publication Critical patent/DE69920697D1/de
Publication of DE69920697T2 publication Critical patent/DE69920697T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69920697T 1998-06-23 1999-06-21 Adenosinderivate Expired - Lifetime DE69920697T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9813554 1998-06-23
GBGB9813554.4A GB9813554D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/004182 WO1999067262A1 (en) 1998-06-23 1999-06-21 Adenosine derivatives

Publications (2)

Publication Number Publication Date
DE69920697D1 true DE69920697D1 (de) 2004-11-04
DE69920697T2 DE69920697T2 (de) 2005-02-24

Family

ID=10834247

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920697T Expired - Lifetime DE69920697T2 (de) 1998-06-23 1999-06-21 Adenosinderivate

Country Status (40)

Country Link
US (2) US6492348B1 (de)
EP (2) EP1090019B1 (de)
JP (2) JP3378240B2 (de)
KR (1) KR100612797B1 (de)
CN (2) CN1202118C (de)
AP (1) AP2000002014A0 (de)
AR (1) AR018917A1 (de)
AT (1) ATE277941T1 (de)
AU (1) AU758018B2 (de)
BG (1) BG65064B1 (de)
BR (1) BR9911498A (de)
CA (1) CA2335520C (de)
CO (1) CO5040216A1 (de)
DE (1) DE69920697T2 (de)
EA (1) EA003828B1 (de)
EE (1) EE04853B1 (de)
ES (1) ES2226399T3 (de)
GB (1) GB9813554D0 (de)
GE (1) GEP20032958B (de)
HK (1) HK1034978A1 (de)
HR (1) HRP20000896B1 (de)
HU (1) HUP0102453A3 (de)
ID (1) ID27484A (de)
IL (2) IL140284A0 (de)
IS (1) IS5773A (de)
MY (1) MY122481A (de)
NO (1) NO318788B1 (de)
NZ (1) NZ508915A (de)
OA (1) OA11574A (de)
PE (1) PE20000704A1 (de)
PL (1) PL194087B1 (de)
PT (1) PT1090019E (de)
RS (1) RS50042B (de)
SI (1) SI1090019T1 (de)
SK (1) SK19582000A3 (de)
TR (1) TR200100449T2 (de)
TW (1) TW541312B (de)
UA (1) UA64794C2 (de)
WO (1) WO1999067262A1 (de)
ZA (1) ZA200007514B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
WO2001064202A2 (en) * 2000-03-01 2001-09-07 Euro-Celtique S.A. Tramadol for the treatment of functional gastrointestinal disorders
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
GB0115182D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Medicaments
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN1636009A (zh) * 2002-02-19 2005-07-06 Cv医药有限公司 A1 腺苷受体的部分和全促效药
EP1513858A2 (de) * 2002-06-17 2005-03-16 Glaxo Group Limited Verfahren zur herstellung von heterocyclyl-substituierten adenosinderivaten
CN100480255C (zh) * 2002-08-15 2009-04-22 Cv医药有限公司 A1腺苷受体的部分和完全激动剂
AU2003292255A1 (en) * 2002-12-18 2004-07-09 Glaxo Group Limited Polymorph
WO2004055032A1 (en) * 2002-12-18 2004-07-01 Glaxo Group Limited Adenosine derivative in polymorph v form
AU2003290088A1 (en) * 2002-12-18 2004-07-09 Glaxo Group Limited Adenosine derivative in polymorph iv form
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
WO2005053712A1 (en) * 2003-12-02 2005-06-16 Glaxo Group Limited Use of adenonsine derivatives for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, niddm
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
AR060607A1 (es) * 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
RU2009121819A (ru) * 2006-11-10 2010-12-20 Новартис АГ (CH) Производные моноацетата циклопентендиола
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CN101712709A (zh) 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
US20150038445A1 (en) * 2012-02-11 2015-02-05 Academia Sinica Methods and compositions for treating pain
CN107278205A (zh) * 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
CN108864099A (zh) * 2018-09-08 2018-11-23 湖北荆洪生物科技股份有限公司 一种高纯6-糠氨基嘌呤的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
DK62592D0 (de) * 1992-05-14 1992-05-14 Novo Nordisk As
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
ES2132419T3 (es) * 1993-07-23 1999-08-16 Merrell Pharma Inc Nuevos agentes de nucleosidos 9-n-biciclicos utiles como inhibidores selectivos de citocinas proinflamatorias.
WO1998001459A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998016539A1 (en) * 1996-10-14 1998-04-23 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ID27484A (id) 2001-04-12
EE04853B1 (et) 2007-06-15
CA2335520A1 (en) 1999-12-29
AR018917A1 (es) 2001-12-12
GEP20032958B (en) 2003-04-25
HK1034978A1 (en) 2001-11-09
AU4514699A (en) 2000-01-10
CA2335520C (en) 2007-02-20
ATE277941T1 (de) 2004-10-15
US6492348B1 (en) 2002-12-10
DE69920697T2 (de) 2005-02-24
BR9911498A (pt) 2001-03-20
US6677316B2 (en) 2004-01-13
AU758018B2 (en) 2003-03-13
BG105155A (en) 2001-09-28
SK19582000A3 (sk) 2001-11-06
EP1090019A1 (de) 2001-04-11
CO5040216A1 (es) 2001-05-29
US20030096788A1 (en) 2003-05-22
KR20010083067A (ko) 2001-08-31
EP1090019B1 (de) 2004-09-29
TW541312B (en) 2003-07-11
NO20006520D0 (no) 2000-12-20
PE20000704A1 (es) 2000-08-03
OA11574A (en) 2004-07-21
NO318788B1 (no) 2005-05-09
NO20006520L (no) 2001-02-14
IL140284A (en) 2006-04-10
CN1202118C (zh) 2005-05-18
PT1090019E (pt) 2005-01-31
EP1447407A1 (de) 2004-08-18
RS50042B (sr) 2008-11-28
TR200100449T2 (tr) 2001-08-21
ES2226399T3 (es) 2005-03-16
PL345089A1 (en) 2001-12-03
JP3378240B2 (ja) 2003-02-17
HRP20000896B1 (en) 2006-03-31
MY122481A (en) 2006-04-29
EA003828B1 (ru) 2003-10-30
HUP0102453A2 (hu) 2002-04-29
CN1314910A (zh) 2001-09-26
JP2003040891A (ja) 2003-02-13
IL140284A0 (en) 2002-02-10
EE200000784A (et) 2002-04-15
SI1090019T1 (en) 2005-02-28
YU82800A (sh) 2003-04-30
EA200001222A1 (ru) 2001-08-27
PL194087B1 (pl) 2007-04-30
HRP20000896A2 (en) 2001-12-31
JP2002518509A (ja) 2002-06-25
CN1616459A (zh) 2005-05-18
ZA200007514B (en) 2002-01-23
AP2000002014A0 (en) 2000-12-31
KR100612797B1 (ko) 2006-08-17
UA64794C2 (en) 2004-03-15
WO1999067262A1 (en) 1999-12-29
GB9813554D0 (en) 1998-08-19
BG65064B1 (bg) 2007-01-31
NZ508915A (en) 2003-09-26
IS5773A (is) 2000-12-15
HUP0102453A3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
DE69920697D1 (de) Adenosinderivate
NO20010193D0 (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
DK1117669T3 (da) Antiviruspurinderivater
ATE256123T1 (de) Pyrimidonderivate
NO20010514L (no) Aminometylkarboksylsyre-derivater
ATE310742T1 (de) C-4ß-SUBSTITUTIERTE MACROLID-DERIVATE
NO20006267D0 (no) Imidazolyl-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
ATE377018T1 (de) Erythromycinderivate
PT928790E (pt) Derivados de tiazolo
PT1089964E (pt) Derivados de hidrazina
ATE231508T1 (de) Azyklische nukleosidderivate
PT1056716E (pt) Derivados de ciclo-hexanodiolo
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE233253T1 (de) Chromanderivate
DK1060183T3 (da) 5-deoxycytidinderivater
PT1123283E (pt) Derivados de tiazole
NO964735D0 (no) Adenosin-derivater
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
PT928793E (pt) Derivados de tiazol
PT1133471E (pt) Derivados de hidrazina
DK1090019T3 (da) Adenosinderivater
NO993562D0 (no) Gemcitabine derivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition